Patient ALMA_7_BM (60 + years, female; coverage 15.74x), residual AML with KMT2A rearrangement (10% blasts), was predicted as MDS-related AML but with a second likely call of AML with t(v;11q23); KMT2A-r, confirmed genomically by detection of KMT2A-CREBBP fusion. The gene discussed is KMT2A; the disease is myelodysplastic syndrome.